Bcl-2, a mitochondrial inner membrane anti-apoptotic protein (Hockenbery et al. 1990), should be particularly discussed, because its prognostic importance in DLBCL has been confirmed by numerous studies (Moni et al. 1999; Rantanen et al. 2001; Shivakumar and Armitage, 2006) and bcl-2 associated treatment resistance can be abolished by the addition of rituximab to CHOP-therapy regimens (Mounier et al. 2003; Coiffier 2005). Here, BCL2 is linked to diffuse large B-cell lymphoma.